Laura E Bauman1,2, Ye Xiong3, Tomoyuki Mizuno3,4, Philip Minar2,4, Tsuyoshi Fukuda3,4, Min Dong3,4, Michael J Rosen2,4, Alexander A Vinks2,4. 1. Department of Pediatrics, University of California San Diego, La Jolla, California, USA. 2. Division of Gastroenterology, Hepatology, and Nutrition, Cincinnati, Ohio, USA. 3. Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA. 4. Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
Abstract
BACKGROUND: Many pediatric patients with inflammatory bowel disease (IBD) lose response to infliximab (IFX) within the first year, and achieving a minimal target IFX trough concentration is associated with higher remission rates and longer durability. Population pharmacokinetic (PK) modeling can predict trough concentrations for individualized dosing. The object of this study was to refine a population PK model that accurately predicts individual IFX exposure during maintenance therapy using longitudinal real-practice data. METHODS: We exported data from the electronic health records of pediatric patients with IBD treated with originator IFX at a single center between January 2011 and March 2017. Subjects were divided into discovery and validation cohorts. A population PK model was built and then validated. RESULTS: We identified 228 pediatric patients with IBD who received IFX and had at least 1 drug concentration measured, including 135 and 93 patients in the discovery and validation cohorts, respectively. Weight, albumin, antibodies to IFX (ATI) detected by a drug-tolerant assay, and erythrocyte sedimentation rate (ESR) were identified as covariates significantly associated with IFX clearance and incorporated into the model. The model exhibited high accuracy for predicting target IFX trough concentrations with an area under the receiver operating characteristic curve (AUROC) of 0.86 (95% confidence interval [CI], 0.81-0.91) for population-based predictions without prior drug-level input. Accuracy increased further for individual-based predictions when prior drug levels were known, with an AUROC of 0.93 (95% CI, 0.90-0.97). CONCLUSIONS: A population PK model utilizing weight, albumin, ordinal drug-tolerant ATI, and ESR accurately predicts IFX trough concentrations during maintenance therapy in real-practice pediatric patients with IBD. This model, which incorporates dynamic clinical information, could be used for individualized dosing decisions to increase response durability.
BACKGROUND: Many pediatric patients with inflammatory bowel disease (IBD) lose response to infliximab (IFX) within the first year, and achieving a minimal target IFX trough concentration is associated with higher remission rates and longer durability. Population pharmacokinetic (PK) modeling can predict trough concentrations for individualized dosing. The object of this study was to refine a population PK model that accurately predicts individual IFX exposure during maintenance therapy using longitudinal real-practice data. METHODS: We exported data from the electronic health records of pediatric patients with IBD treated with originator IFX at a single center between January 2011 and March 2017. Subjects were divided into discovery and validation cohorts. A population PK model was built and then validated. RESULTS: We identified 228 pediatric patients with IBD who received IFX and had at least 1 drug concentration measured, including 135 and 93 patients in the discovery and validation cohorts, respectively. Weight, albumin, antibodies to IFX (ATI) detected by a drug-tolerant assay, and erythrocyte sedimentation rate (ESR) were identified as covariates significantly associated with IFX clearance and incorporated into the model. The model exhibited high accuracy for predicting target IFX trough concentrations with an area under the receiver operating characteristic curve (AUROC) of 0.86 (95% confidence interval [CI], 0.81-0.91) for population-based predictions without prior drug-level input. Accuracy increased further for individual-based predictions when prior drug levels were known, with an AUROC of 0.93 (95% CI, 0.90-0.97). CONCLUSIONS: A population PK model utilizing weight, albumin, ordinal drug-tolerant ATI, and ESR accurately predicts IFX trough concentrations during maintenance therapy in real-practice pediatric patients with IBD. This model, which incorporates dynamic clinical information, could be used for individualized dosing decisions to increase response durability.
Authors: Johannan F Brandse; Diane Mould; Oscar Smeekes; Yaël Ashruf; Sabine Kuin; Anne Strik; Gijs R van den Brink; Geert R DʼHaens Journal: Inflamm Bowel Dis Date: 2017-04 Impact factor: 5.325
Authors: David Drobne; Peter Bossuyt; Christine Breynaert; Tom Cattaert; Niels Vande Casteele; Griet Compernolle; Matthias Jürgens; Marc Ferrante; Vera Ballet; Willem-Jan Wollants; Isabelle Cleynen; Kristel Van Steen; Ann Gils; Paul Rutgeerts; Severine Vermeire; Gert Van Assche Journal: Clin Gastroenterol Hepatol Date: 2014-07-25 Impact factor: 11.382
Authors: Jean Frédéric Colombel; William J Sandborn; Walter Reinisch; Gerassimos J Mantzaris; Asher Kornbluth; Daniel Rachmilewitz; Simon Lichtiger; Geert D'Haens; Robert H Diamond; Delma L Broussard; Kezhen L Tang; C Janneke van der Woude; Paul Rutgeerts Journal: N Engl J Med Date: 2010-04-15 Impact factor: 91.245
Authors: Thomas Van Stappen; Niels Vande Casteele; Gert Van Assche; Marc Ferrante; Séverine Vermeire; Ann Gils Journal: Gut Date: 2017-04-27 Impact factor: 23.059
Authors: Niels Vande Casteele; Reena Khanna; Barrett G Levesque; Larry Stitt; G Y Zou; Sharat Singh; Steve Lockton; Scott Hauenstein; Linda Ohrmund; Gordon R Greenberg; Paul J Rutgeerts; Ann Gils; William J Sandborn; Séverine Vermeire; Brian G Feagan Journal: Gut Date: 2014-10-21 Impact factor: 23.059
Authors: W Byon; M K Smith; P Chan; M A Tortorici; S Riley; H Dai; J Dong; A Ruiz-Garcia; K Sweeney; C Cronenberger Journal: CPT Pharmacometrics Syst Pharmacol Date: 2013-07-03
Authors: Yizhen Guo; Lai Wei; Sandip H Patel; Gabrielle Lopez; Madison Grogan; Mingjia Li; Tyler Haddad; Andrew Johns; Latha P Ganesan; Yiping Yang; Daniel J Spakowicz; Peter G Shields; Kai He; Erin M Bertino; Gregory A Otterson; David P Carbone; Carolyn Presley; Samuel K Kulp; Thomas A Mace; Christopher C Coss; Mitch A Phelps; Dwight H Owen Journal: Clin Lung Cancer Date: 2022-01-08 Impact factor: 4.840
Authors: Hsuan Ping Chang; Valentina Shakhnovich; Adam Frymoyer; Ryan Sol Funk; Mara L Becker; K T Park; Dhaval K Shah Journal: Br J Clin Pharmacol Date: 2021-07-19 Impact factor: 3.716